Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by Stifel Nicolaus from $300.00 to $345.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 34.89% from the company’s previous close.

A number of other analysts have also recently commented on the company. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Canaccord Genuity Group raised their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday, March 21st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $316.25.

Alnylam Pharmaceuticals Stock Down 5.3 %

NASDAQ ALNY opened at $255.76 on Monday. The stock has a market capitalization of $33.27 billion, a P/E ratio of -117.86 and a beta of 0.39. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a fifty day moving average of $260.15 and a 200-day moving average of $260.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $28,000. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $33,000. OFI Invest Asset Management bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.